netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Search
 Formulary Chapter 2: Cardiovascular system - Full Chapter
02.08.01  Expand sub section  Parenteral anticoagulants
Argatroban (Exembol)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

50mg/50mL solution for infusion vials
250mg/2.5mL concentrate for solution for infusion vials

Restriction: For use when danaparoid is not available.

Anticoagulation in patients with heparin induced thrombocytopenia
1st line for Renal & Critical Care patients

 
   
02.08.01  Expand sub section  Heparin
Heparin 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

Solution for injection ampoules/ vials
All Heparin Infusion bags

These are all hospital only prescribing only. The heparin flushes listed below may be prescribed in primary care.

 
   
Heparin unfractionated flushes

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Heparin sodium 50 units/5ml patency solution ampoules
Heparin sodium 50 units/5ml i.v flush solution ampoules

Heparin sodium 200 units/2ml patency solution ampoules
Heparin sodium 200 units/2ml i.v flush solution ampoules

These are flushes for maintaining patency of peripheral venous catheters- note there are two strengths, so confirm with original specialist which is needed.

 
   
02.08.01  Expand sub section  Low molecular weight heparins
Dalteparin Sodium  
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber E

Solution for injection ampoules/ pre-filled syringes

In Obstetrics

Link to ESCA

 
   
Dalteparin Sodium  
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber E

Solution for injection ampoules/ pre-filled syringes

Treatment of DVT and PE in adult cancer patients

Link to ESCA

 
   
Dalteparin Sodium  
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Solution for injection ampoules/ pre-filled syringes

Treatment of DVT and PE in medical patients

 

 
   
02.08.01  Expand sub section  Heparinoids
Danaparoid 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

750units/ 0.6mL solution for injection ampoules

Restriction: For heparin induced thrombocytopenia only

 
   
02.08.01  Expand sub section  Hirudins to top
Bivalirudin (Angiox)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

250mg powder for concentrate for solution for infusion vials

Restriction: Initiation by Cardiology consultants only and should only be used during percutaneous coronary intervention (PCI) procedure

 
Link  NICE TA230 : Bivalirudin for the treatment of ST-segment-elevation myocardial infarction
   
02.08.01  Expand sub section  Epoprostenol
Epoprostenol (Flolan)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

500mcg powder for solution for infusion vials
1.5mg powder for solution for infusion vials

Restriction: Consultant use only

Restriction: In accordance with NHS England prescribing policy

MHRA advice: Veletri (epoprostenol) powder for solution for infusion: incompatibilities with some models of administration devices (December 2014)

 
Link  MHRA Guidance on Epoprostenol (Veletri)
Link  NHSE: National policy for targeted therapies for the treatment of pulmonary hypertension in adults
   
02.08.01  Expand sub section  Fondaparinux
Fondaparinux (Arixtra)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

Solution for injection pre-filled syringes

Restriction: For patients with unstable angina and non-ST elevation myocardial infarction

 
   
Fondaparinux 
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Grey

Not approved for inclusion in the North Staffordshire Joint Formulary for the prevention and treatment of venous thromboembolic events 

 

 

 
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG
Blueteq
High Cost Drug Approval System

Traffic Light Status Information

Status Description

Red

Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available   

Amber

Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.   

Amber E

Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary  

Green

Medicines which can be prescribed in either Primary or Secondary Care.  

Grey

These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.  

netFormulary